Atormac
Neurology India
Open access journal indexed with Index Medicus
  Users online: 1120  
 Home | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (3,767 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Materials and Me...
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed513    
    Printed23    
    Emailed0    
    PDF Downloaded37    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2018  |  Volume : 66  |  Issue : 3  |  Page : 733-738

Spectrum of metastatic neoplasms of the brain: A clinicopathological study in a tertiary care cancer centre


1 Department of Pathology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
2 Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India
3 Department of Radiation Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India

Date of Web Publication15-May-2018

Correspondence Address:
Dr. Usha Amirtham
Department of Pathology, Kidwai Cancer Institute, Hosur Road, Bengaluru - 560 029, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.232333

Rights and Permissions

 » Abstract 


Background: While brain metastases (BM) are the most common causes of neurologic disorders in patients with known systemic malignancies, they can often be the initial manifestations of an undetected primary elsewhere. BM are major causes of morbidity and mortality in cancer patients.
Aims: We describe a mixed population (data from both retrospective and prospective collection) having a BM from a solid tumor. We report the percentage distribution of the most frequent types of BM, confirming the data published in the literature. This paper may play a role in presenting the Southeast Asian reality compared with the Western countries.
Setting: A tertiary-care cancer centre.
Materials and Methods: Data for 4 years were retrieved from the records of the Department of Pathology of our institute. Hematolymphoid and meningeal tumors were excluded. Hematoxylin and eosin (H and E) stained slides were reviewed, and in cases with an unknown primary, immunohistochemistry (IHC) was advised. The panel of markers was chosen based on the histomorphology on H and E sections. IHC was done in cases with an unknown primary where paraffin blocks were available.
Results: Lung cancer was found to be the most common primary malignancy (n = 30; 48.4%) followed by breast cancer (n = 13; 21%), colorectal cancer (n = 6; 9.6%), and skin cancer (melanoma) [n = 3; 4.8%].
Conclusion: The incidence of BM from lung and breast cancer was similar to that seen in the Western studies. However, BM from colorectal cancer and melanoma show a higher and lower incidence, respectively, in comparison with the Western literature.


Keywords: Brain metastases, central nervous system metastases, immunohistochemistry, metastatic carcinoma
Key Messages:
Brain metastases (BM) can often be the initial manifestation of an undetected primary elsewhere. On histological and immunohistochemistry assessment of specimens of solid metastases in the brain, the incidence of BM from lung and breast cancer were similar to that seen in Western studies and BM from colorectal cancer showed a higher, and melanoma showed a lower incidence, respectively.


How to cite this article:
Singh S, Amirtham U, Premalata CS, Lakshmaiah KC, Viswanath L, Kumar RV. Spectrum of metastatic neoplasms of the brain: A clinicopathological study in a tertiary care cancer centre. Neurol India 2018;66:733-8

How to cite this URL:
Singh S, Amirtham U, Premalata CS, Lakshmaiah KC, Viswanath L, Kumar RV. Spectrum of metastatic neoplasms of the brain: A clinicopathological study in a tertiary care cancer centre. Neurol India [serial online] 2018 [cited 2018 Dec 15];66:733-8. Available from: http://www.neurologyindia.com/text.asp?2018/66/3/733/232333




Brain metastases (BM) are devastating lesions with a huge impact on the survival and quality of life of patients. The World Health Organisation (WHO) has defined metastatic tumors of the central nervous system (CNS) as “tumors that originate outside the CNS and spread secondarily to the CNS via the hematogenous route (metastasis) or by direct invasion from adjacent tissues.”[1]

Metastatic tumors are the most common CNS neoplasms.[2] The incidence of metastases to the brain is estimated to be about 170,000/year in the USA, an incidence 10 times higher than that of primary malignant brain tumors.[3] It has been reported that between 20% and 40% of patients with systemic cancer will develop metastases involving the CNS during the course of their disease.[3]

The morbidity and mortality rates are high in patients who develop BM.[4] In adults, metastases to the brain most commonly arise from primary tumors of the lung (50–60%), breast (15–20%), skin (melanoma) [5–10%], and gastrointestinal (GI) tract (4–6%).[5],[6] The most common sources in children, in a descending order, are leukemia, lymphoma, osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma.[2]

The increase in the incidence of BM is likely a result of improved therapeutics resulting in increased survival after the initial diagnosis has been established, an aging patient population, and improved screening and diagnostic methods, leading to the earlier detection of the lesion and the initiation of treatment.[2],[7] With the emergence of newer and better imaging techniques, confirmatory diagnosis of the brain neoplasm by histopathology has become easier.[8] However, up to 15% of all patients with BM have no clearly detectable primary site despite an extensive evaluation.[9],[10],[11] Immunohistochemical analysis is most helpful for determining the exact nature and origin of the metastatic neoplasm and for distinguishing primary from secondary CNS tumors in some cases.[12],[13],[14]


 » Materials and Methods Top


This study was conducted at the Department of Pathology at our institute. Data for 4 years were retrieved from the records both retrospectively (January 2012 to December 2013) and prospectively (January 2014 to December 2015). Hematolymphoid and meningeal tumors were excluded. Hematoxylin and eosin (H and E) stained slides were reviewed (n = 69), and in cases with an unknown primary (n = 46), immunohistochemistry (IHC) was advised. The panel of markers was chosen based on the histomorphology on the H and E sections. IHC was done in cases with an unknown primary where paraffin blocks were available (n = 39).

IHC was done on 3-μ paraffin sections taken on 3-amino propyl ethoxy silane (APES) coated slides, using prediluted antibodies, with known positive controls, by the polymer horse radish peroxidase (HRP) IHC detection system, using the manufacturer's instructions. The slides were stained with 3, 3'-diaminobenzidine tetra hydrochloride (DAB) chromogen, counterstained with hematoxylin and mounted. The details of the antibodies used are given in [Table 1].
Table 1: Details of the antibodies used

Click here to view



 » Results Top


During the study period, we encountered 69 cases of metastatic brain neoplasms. The male-to-female ratio was 1.2:1. The age of the patients ranged from 21–80 years, and the mean age was 51.75 years. Majority of the cases were encountered in the fifth and sixth decades. Most of the patients presented with symptoms of raised intracranial pressure, which included headache (n = 52; 75.4%) and vomiting (n = 43; 62.3%), as well as seizures (n = 21; 30.4%). The most common presentation was with headache followed by vomiting and seizures. Twenty-three cases (33.3%) had a known primary malignancy. Among these, lung cancer was the most common primary (9 cases) followed by breast cancer (6 cases). In the remaining 46 (66.7%) cases, the primary was unknown. Paraffin blocks were available in 39 out of 46 cases, on which IHC was done. After the IHC, lung cancer (53.8%) was the most common primary to be detected followed by breast cancer (17.9%) and colorectal cancer (10.3%). Adenocarcinoma of the lung was the most common subtype of lung cancer followed by small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma. We did not encounter any cases of squamous cell carcinoma of the lung as a source of BM in our study. Details of the different subtypes of primary malignancies encountered are outlined [Table 2]. IHC was inconclusive in two cases where a morphologic diagnosis of metastatic adenocarcinoma and metastatic poorly differentiated carcinoma was given. On studying the metastatic brain neoplasms and their IHC findings, lung cancer was found to be the most common primary malignancy (n = 30; 48.4%) followed by breast cancer (n = 13; 21%), colorectal cancer (n = 6; 9.6%), and skin cancer (melanoma) [n = 3; 4.8%]. Other sites of primary malignancy included the kidney (n = 2; 3.2%), oesophagus (n = 2; 3.2%), urinary bladder (n = 2; 3.2%), prostate (n = 1; 1.6%), and ovary (n = 1; 1.6%). The lung was the most common site of primary in both men (47.4%) and women (38.7%). In 9 cases (13%), we could not determine the primary site of malignancy, as paraffin blocks were not available in 7 cases and IHC was inconclusive in 2 cases. Photomicrographs of the different malignancies and their corresponding IHC profiles are given in [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7].
Table 2: Details of the different subtypes of primary malignancies encountered

Click here to view
Figure 1: Brain metastases from lung adenocarcinoma (H and E, ×10) in (a), with tumor cells positive for TTF1 (×10) in b and c (×40). Tumor cells showing membranous positivity for CK7 (×10) in (d)

Click here to view
Figure 2: Brain metastases from breast carcinoma (invasive carcinoma, NOS) (H and E, ×10) in (a) and (H and E ×40) in (b). Tumor cells are positive for ER (×10) in (c) and HER2 (Score=3; ×10) in (d)

Click here to view
Figure 3: Brain metastases from signet ring cell carcinoma, rectum (H and E, ×10) in (a). Tumor cells are positive for CK7 (×10) in (b), CK20 in (c) (×10) and CDX2 (×10) in (d)

Click here to view
Figure 4: Brain metastasis from high grade serous carcinoma, ovary (H and E, ×10) in (a). Tumor cells are positive for WT1 (×10) in (b), ER (×10) in (c), and CK7 (×10) in (d)

Click here to view
Figure 5: Brain metastases from high grade urothelial carcinoma, urinary bladder (H and E, ×10) in (a) and (H and E, ×40) in (b). Tumor cells showing strong membranous positivity for CK20 (×40) in (c) and CK7 (×10) in (d)

Click here to view
Figure 6: Brain metastases from clear cell carcinoma, kidney (H and E, ×10) in (a). Tumor cells positive for CD10 (×10) in (b)

Click here to view
Figure 7: Brain metastases from melanoma, skin (H and E, ×10) in (a) and squamous cell carcinoma, oesophagus (H and E, ×10) in (b)

Click here to view


We also determined the proportion of metastatic brain neoplasms and found that they accounted for 4.9% of all malignant brain neoplasms in our centre, which is a referral centre for radiotherapy of brain tumors.


 » Discussion Top


Despite considerable progress in diagnostic modalities and therapeutics, successful treatment of cancer remains a major challenge. This increase in incidence can be attributed to the growth of the world's aging population and the fact that cancer remains a leading cause of mortality worldwide.[15] BM are frequently discovered in cancer patients and are said to be far more common than primary brain tumors. Approximately 25% of patients who die from cancer have CNS metastases which are detected at autopsy, of which approximately 15% are in the brain, and in approximately 10% patients, brain is the only site of CNS metastases.[16]

Traditionally, a pathologist's role in the diagnosis of a brain metastasis has been to determine the absence of a high-grade glial neoplasm followed by a simple diagnosis of “metastatic neoplasm” or a “metastatic carcinoma.” For many years, the diagnosis of BM was based only on the examination of H and E stained slides, and in the event of suspicion of an adenocarcinoma, special stains such as the mucicarmine stain were used to demonstrate the presence of mucin. However, identification of the possible primary neoplasms was difficult, especially in poorly differentiated neoplasms, resulting in difficulty in determining the origin of the neoplasm when there was no history of a previous malignancy. Identification of the possible primary neoplasms was difficult in asymptomatic patients with an occult primary neoplasm. With the advent of IHC in the 1980s, it became easier to determine the primary tumor and to provide an early and adequate therapy to patients with BM, resulting in an increased survival of these patients.

An important factor affecting the incidence of metastatic brain tumors is the histology of the primary tumor.[2] In general, the primary tumors which serve as sources of BM (in descending order) are those arising in the lung, breast, skin, kidney, and gastrointestinal (GI) tract.[5],[6],[17],[18],[19]

Other factors that have been reported to affect the incidence of BM are the stage of the primary malignancy, age, sex, and race.[2],[11]

The age at diagnosis of the primary malignancy has a significant effect on the incidence of BM. Metastatic brain tumors are more common in adults, with their incidence peaking in the age group of 50–80 years.[20],[21],[22] Although majority of the patients with BM belong to the older population with cancer, younger adult patients with cancer may have a higher proportion of BM.[2] This might be because of differences in biology and a more aggressive cancer phenotype in younger adult patients.[2]

Only two Indian studies on the histopathology of metastases in the CNS with immunohistochemical findings have been published till date. Patnayak et al., conducted an 11-year retrospective study of 40 cases of BM in a tertiary care centre in South India, and found that adenocarcinoma (56.67%) was the most common source of metastases to the brain.[8] The lung was the most common source of metastatic adenocarcinoma followed by the thyroid and prostate among the cases with a known primary. However, in approximately 47% of cases harbouring a metastatic adenocarcinoma, the primary site was unknown.[8] Metastatic squamous cell carcinoma was the next in frequency (16.67%) followed by metastatic melanoma (of the skin) [6.67%], metastatic germ cell tumor (6.67%), and metastatic neuroendocrine carcinoma (lung; 3.33%). Ten percent of BM were undifferentiated.[8] Sharma et al., conducted a study of 74 cases of BM from an unknown primary over a period of 64 months and found the lungs to be the most common primary for BM of unknown origin (n = 51; 68.9%).[12] They also found that the use of IHC helped them to identify the primary tumor in 86% of BM cases with an unknown primary.[12] The present study also shows the lung to be the most common site of primary tumor (48.4%).

The proportion of BM in the present study was 4.9%, which is lower than that seen by Jaiswal et al., in a study conducted at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru. The figure was also lower than that seen in the Western literature.[23],[24] This can be attributed to various reasons. Our institute is an oncology referral centre, where postoperative radiotherapy is offered but no neurosurgery is performed. Many patients with BM diagnosed elsewhere do not opt for further workup and treatment at all after learning about the dismal prognosis of their condition. The poor economic status of most patients could be the main reason for this. However, compliance towards postoperative radiotherapy for primary brain tumors is much better. The present series is also based entirely on surgical pathology material because no autopsy samples were available. The frequency of BM from lung and breast cancers in our study was similar to that cited in the existing literature. However, BM from colorectal cancer was found to be more frequent than BM from melanoma and renal cancer, in contrast to the existing data.[5],[6],[17],[18],[19]

In lung cancer, the histological subtype is the most important risk factor for the development of BM. Patients with small cell lung cancer (SCLC) have the highest risk (approximately 70%) for developing BM.[25] It is because of this that SCLC is the only subtype with a clear indication for prophylactic whole brain radiation to prevent the development of BM.[26] We had two cases of SCLC (7% of all lung primaries), both of which were diagnosed by IHC in cases with an unknown primary.

The incidence of BM varies from 5–30% among patients with metastatic breast cancer. This is dependent on the molecular subtype, whose surrogate IHC markers are steroid receptor status [estrogen receptor (ER), progesterone receptor (PR)], HER2 overexpression status, and rate of proliferation. HER2 overexpression is reflected in intense membranous overexpression of the HER2 receptor and is frequently associated with the development of BM.[27] The triple negative subtype of breast carcinoma is defined by the absence of hormone and HER2 receptor overexpression, and is associated with the highest propensity for development of BM.[28],[29] However, in our study, almost all the cases were positive for ER (Allred score = 3 or more) and PR (Allred score = 3 or more), except one which was triple negative. HER2 overexpression was seen in 4 cases (score = 3+), equivocal in 2 cases (score = 2+), and negative in one case (score = 1+) [triple negative case]. Multiple metastases were seen in a known case of invasive carcinoma breast, no special type.

BM from colorectal cancer account for 1.4–4.8% cases of BM.[2],[4],[30] We found that BM from colorectal cancer constituted 8.7% of all our cases. This figure could be explained by the increased survival of patients with colorectal cancer due to improved treatment methods, and hence, an increased likelihood of developing BM as a late complication.

Cutaneous melanoma accounted for 4.8% of BM in our study. This is much lower than the incidence of 40% found in Western studies.[4],[31],[32],[33],[34] Apart from the lower incidence of melanoma in our population, the lack of autopsy cases could account for this finding. In the study conducted by Patnayak et al., a melanoma accounted for 5% of the cases, which is similar to our findings, whereas Sharma et al., did not encounter any case of BM from a melanoma.[8],[12]

BM from clear cell renal cell carcinoma accounted for 3.2% of the cases. Their reduction could be due to the improved systemic treatment strategies including antiangiogenic tyrosine kinase inhibitors. Sharma et al., found that renal cell carcinoma accounted for 2.7% of the cases of BM, which is similar to our findings.[12]

Rare causes of BM are ovarian cancer, prostate cancer, bladder cancer, and gastroesophageal cancer. This was concordant with our findings.[34]


 » Conclusion Top


BM are often the first signs of an occult malignancy and their accurate diagnosis can help point towards the site of the primary malignancy, which can then guide optimal treatment. In the present study, most of the BM represented metastases of unknown origin (MUOs), with IHC determining the primary, most commonly in the lung, breast, and colorectum. Hence, the role of the pathologist is of utmost importance because a definitive diagnosis can be made with an easily available ancillary test such as IHC.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Wesseling P, von Deimling A, Aldape KD. Metastatic tumors of the CNS. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO Classification of Tumours of the Central Nervous System. IARC: Lyon; 2007. pp 247-51.  Back to cited text no. 1
    
2.
Suki D. The epidemiology of brain metastases. In: Sawaya R, editor. Intracranial metastases; Current management strategies. Malden (MA): Blackwell; 2004. pp 20.  Back to cited text no. 2
    
3.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1999;49:8-31.  Back to cited text no. 3
[PUBMED]    
4.
Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-705.  Back to cited text no. 4
[PUBMED]    
5.
Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533-40.  Back to cited text no. 5
[PUBMED]    
6.
Wen PY, Loeffler JS. Brain metastases. Curr Treat Options Oncol 2000;1:447-58.  Back to cited text no. 6
[PUBMED]    
7.
Barnholtz–Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72.  Back to cited text no. 7
    
8.
Patnayak R, Jena A, Vijaylaxmi B, Lakshmi AY, Prasad BCM, Kumar A, et al. Metastasis in central nervous system: Clinicopathological study with review of literature in a tertiary care centre in South India. South Asian J Cancer 2013;2:245-9.  Back to cited text no. 8
[PUBMED]  [Full text]  
9.
Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery and survival. Cancer 1996;78:1781-8.  Back to cited text no. 9
[PUBMED]    
10.
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys1999;43:795-803.  Back to cited text no. 10
[PUBMED]    
11.
Patchell R. Brain metastases. Handbook Neurol 1997;25:135-49.  Back to cited text no. 11
    
12.
Sharma P, Trivedi P, Shah MJ. Evaluation of central nervous system metastases with immunohistochemistry correlation. Indian J Pathol Microbiol 2014;57:376-9.  Back to cited text no. 12
[PUBMED]  [Full text]  
13.
Becher MW, Abel TW, Thompson RC, Weaver KD, Davis LE. Immunohistochemical analysis of metastatic neoplasms of the central nervous system. J Neuropathol Exp Neurol 2006;65:935-44.  Back to cited text no. 13
[PUBMED]    
14.
Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004;200:727-34.  Back to cited text no. 14
[PUBMED]    
15.
Posner JB. Brain metastases: 1995. A brief review. J Neuro-Oncol 1996;27:287-93.  Back to cited text no. 15
    
16.
Gavrilovic IT, Posner JB. Brain metastases: Epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.  Back to cited text no. 16
[PUBMED]    
17.
Sawaya R, Bindal RK, Lang FF, Abi–Said D. Metastatic brain tumors. In: Kaye AH, Laws Jr ER, editors. Brain tumors. An encyclopedic approach. London: Churchill Livingstone; 2001. pp 999-1026.  Back to cited text no. 17
    
18.
Weinberg JS, Lang FF, Sawaya R. Surgical management of brain metastases. Curr Oncol Rep 2001;3:476-83.  Back to cited text no. 18
[PUBMED]    
19.
Graf AH, Buchberger W, Langmayr H, Schmid KW. Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol 1988;412:493-8.  Back to cited text no. 19
[PUBMED]    
20.
Takakura K, Sano K. Clinical features of intracranial metastatic tumors. In: Takakura K, Sano K, Hojo S, Hirano A, editors. Metastatic tumors of the central nervous system. Tokyo-New York: Igaku–Shoin; 1982. pp 112-37.  Back to cited text no. 20
    
21.
Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr 1983;103:558-61.  Back to cited text no. 21
[PUBMED]    
22.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.  Back to cited text no. 22
[PUBMED]    
23.
Jaiswal J, Shastry AH, Ramesh A, Yasha TC, Arivazhagan A, Santosh V. Spectrum of primary intracranial tumors at a tertiary care neurological institute: A hospital – Based brain tumor registry. Neurol India 2016;64:494-501.  Back to cited text no. 23
[PUBMED]  [Full text]  
24.
Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumours estimated from 2007 United States cancer incidence data. Neuro Oncol 2012;14:1171-7.  Back to cited text no. 24
[PUBMED]    
25.
Blanchard P, Le Pechoux C. Prophylactic cranial irradiation in lung cancer. Curr Opin Oncol 2010;22:94-101.  Back to cited text no. 25
    
26.
Paumier A, Cuenca X, Le Pechoux C. Prophylactic cranial irradiation in lung cancer. Cancer Treat Rev 2011;37:261-5.  Back to cited text no. 26
    
27.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.  Back to cited text no. 27
    
28.
Lin NU, Winer EP. Brain metastases: The HER2 paradigm. Clin Cancer Res 2007;13:1648-55.  Back to cited text no. 28
[PUBMED]    
29.
Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009;20:621-7.  Back to cited text no. 29
[PUBMED]    
30.
Patanaphan V, Salazar OM. Colorectal cancer: Metastatic patterns and prognosis. South Med J 1993;86:38-41.  Back to cited text no. 30
[PUBMED]    
31.
Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, et al. Melanoma brain metastasis: Overview of current management and emerging targeted therapies. Expert Rev Neurother 2012;12:1207-15.  Back to cited text no. 31
[PUBMED]    
32.
Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 1978;42:660-8.  Back to cited text no. 32
[PUBMED]    
33.
Shinde SV, Shenoy AS, Savant HV, Balasubramaniam SB. Coexistent intracerebral metastatic melanoma and meningioma. Neurol India 2017;65:110-2.  Back to cited text no. 33
[PUBMED]  [Full text]  
34.
Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: An overview. Anticancer Research 2012;32:4655-62.  Back to cited text no. 34
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow